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Abstract Over recent years, several reports have been
published on unusual cases of osteonecrosis of the jaw
(ONJ) in adults using second- and third-generation nitro-
gen-containing bisphosphonates such as pamidronate,
alendronate, risedronate and zoledronate, but no case has
ever been reported either in children or in adult patients
taking neridronate. Children and adolescents affected by
osteogenesis imperfecta (OI) could belong to a high-risk
group for ONJ because bone fragility in OI is associated
with a connective tissue malfunction. The purpose of this
study is to evaluate the incidence of ONJ in a pediatric
population treated with neridronate for OI. A total of 102
pediatric patients with OI who received neridronate infu-
sions for a mean of 6.81 years (SD ± 3.06 years) were
clinically assessed for possible ONJ. Eligibility criteria for
participation included patients between 1.2 and 24 years
old who received cyclical neridronate infusions for at least
1 year. All the patients were reviewed to determine dura-
tion, dosage and cumulative dose of their bisphosphonate
therapy and were examined clinically to assess their oral
health status. We have not demonstrated any occurrence of
ONJ in our patients. In conclusion, at the moment insuf-
ficient data are available to prove a greater risk of ONJ in
children with OI than in children affected by other forms of
bone fragility. However, cases may emerge in future
because the risk of ONJ seems to be related to the cumu-
lative dose and the duration of therapy.
Keywords Intravenous neridronate 
Osteonecrosis of the jaw  Osteogenesis imperfecta
Abbreviations
ONJ Osteonecrosis of the jaw
OI Osteogenesis imperfecta
Introduction
Osteogenesis imperfecta (OI) is the most common genetic
bone disorder and its prevalence is estimated to be between
1 in 10,000 and 1 in 20,000 births.
The great majority of OI cases are caused by a genetic
defect in the quantitative or qualitative synthesis of the
structural protein type I collagen; however, at the present
time, a surprising genetic complexity of the molecular
bases of OI has been revealed. To date, nine types of OI
have been defined on the basis of a different phenotype
correlated with each gene, but recently a new classification
has emerged which classifies OI in 5 major types [1–3].
Until a gene therapy aimed at either replacement or
silencing of the mutant allele is feasible, the causal defect of
the disease cannot be corrected. At present, bisphospho-
nates are the most promising therapy and their use has
become the widely accepted treatment both in adults and
children affected by OI. Many studies on children with OI
[4–8] suggest that intravenous infusions of bisphosphonates
significantly raise the rate of increase in bone mass density
and significantly decrease the risk of clinical fractures,
because bisphosphonates given at adequate doses improve
bone strength. The action mechanism of bisphosphonates is
complex but these compounds act mainly on osteoclasts by
inhibiting their activity through a direct toxic effect on these
cells [9].
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Intravenous bisphosphonate use in adult patients has
been linked to osteonecrosis of the jaw (ONJ), a condition
which has recently emerged as a significant complication
in a subset of patients taking these drugs, typically [
60 years of age and with a history of malignancy [10–13].
However, increasing frequency of ONJ has also been
reported recently in adults receiving oral bisphosphonates
[12, 14].
In children osteonecrosis of long bones is a well-docu-
mented complication of intensive chemotherapy for acute
lymphoblastic leukemia (ALL), including multiple courses
of corticosteroids [15, 16]; however, no case of osteone-
crosis, specifically of the jaw, has ever been reported in
children.
Over the past few years, several reports have been
published of unusual cases of ONJ in adults using second-
and third-generation nitrogen-containing bisphosphonates
such as pamidronate, alendronate, risedronate and zoledr-
onate [10, 14, 17–22]. In the literature there are no reports
on ONJ in patients using neridronate, a nitrogen-containing
bisphosphonate structurally similar to alendronate and
pamidronate. There are few studies that have assessed the
incidence of ONJ in pediatric populations being treated
with pamidronate, zoledronate or alendronate, but none
concerning neridronate [23–25].
Patients and adolescents affected by OI could belong to
a high-risk group for ONJ because bone fragility in OI is
associated with a connective tissue malfunction.
The purpose of our study is to investigate any possible
relationship between intravenous neridronate treatment and
ONJ in a pediatric population affected by OI and, even-
tually, to establish an incidence of this complication.
Materials and methods
A retrospective survey of 102 pediatric patients who
received neridronate infusions for OI at the Pediatric Clinic
of the University of Verona was carried out between
August 2009 and March 2011. Indications for treatment
were either severe forms of OI with fractures and skeletal
deformities, or milder forms with pain, low growth
velocity, and vertebral compressions.
We included patients having received only neridronate
therapy and no other bisphosphonate treatment.
Eligibility criteria for participation included OI children
or adolescents between 1.2 and 24 years of age who had
received neridronate infusions for at least 1 year.
All the patients were reviewed to determine the type,
treatment starting age, dosage, cumulative dose and dura-
tion of their bisphosphonate therapy; the patients were also
investigated and examined clinically by a dental surgeon to
assess their oral health status.
A confirmed case of ONJ was defined, according to the
American Association of Oral and Maxillofacial Surgeons
(AAOMS), as an area of exposed bone in the maxillofacial
region that does not heal within 8 weeks after being
identified by a health care provider in a patient who is
currently receiving or has been exposed to a bisphospho-
nate and who has not had radiation therapy to the cranio-
facial region [19, 20]. To further distinguish ONJ from
other health conditions, the patients must have taken or be
currently taking bisphosphonate, while other potential
confounding conditions (e.g., radiotherapy to the cranio-
facial region, corticosteroids, diabetes, malignant disease
and cytostatic treatment) must be absent.
A history of any dental procedure, a known risk factor
for osteonecrosis, was carefully reviewed. We looked for
the presence of non-healing ulcers, exposed bone, infec-
tions and abnormal mobility of teeth in the maxilla or
mandible and recorded any cases.
The study was approved by Ethical Committee of the
Hospital and written informed consent was obtained from
each patient and/or guardian.
Results
By the end of the survey, there were 55 female patients
between 3.7 and 23.1 years of age (mean 11.8 ± 5.0 years)
and 47 male patients between 3.1 and 23.4 years (mean
12.8 ± 5.2 years).
Seventy-five patients were suffering from OI type I, 20
patients from OI type III, 4 patients from OI type IV, and 3
patients suffered other rare forms of OI (Table 1).
At the time neridronate treatment began the age varied
from 2 months to 19.6 years of age (mean 5.4 ± 3.9 years).
Fifteen patients started treatment in the first year of life
(mean 4.8 months); nine patients with type III OI, five
patients with type I OI, and one patient with type VII OI.
These patients were treated with neridronate infusions once
every 3–4 months at a dose of 1 mg/kg/day, for two con-
secutive days. All other patients received neridronate infu-
sions once every 3–6 months at a dose of 2 mg/kg/dose in a
single session. The mean cumulative dose was 1,679 mg
(range 144–5,307) and the mean cumulative dose/kg was
50 mg (range 10–100).
Neridronate treatment lasted from 1.0 to 12.9 years
(mean 6.8 ± 3.0 years); the treatment period ranged from
2.0 to 11.5 years (mean 6.9 ± 2.7 years) in type III OI
patients, from 1.2 to 12.9 years (mean 6.7 ± 3.0 years) in
type I OI patients, and from 1.0 to 12.5 years (mean
7.0 ± 4.2 years) in patients suffering from the other forms
of OI.
Only six patients had suspension of the therapy longer
than 3–4 months during the treatment period (one patient
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for 3 years, one patient for 2 years, one patient for
1.24 years, one patient for 1 year, one patient for 9 months,
and one patient for 6 months). Eight patients stopped ne-
ridronate infusions before the analysis (one patient from
4 years, three patients from 3 years, three patients from
2 years, and one patient from 1 year).
Only two patients affected by type I OI had a history of
an invasive dental procedure (abscess of tooth with pulp-
ectomy) during bisphosphonate treatment. The most com-
mon dental finding was clinically apparent dentinogenesis
imperfecta that was detected in 28 patients.
ONJ was not seen in any of the patients who were
assessed. We have not reported evidence that ONJ is a side-
effect of intravenous neridronate use in children and ado-
lescents with OI.
Discussion
The use of bisphosphonates has become the widely
accepted treatment for children and adolescents affected by
OI.
In recent years, several reports have been published on
unusual cases of ONJ in adults using second- and third-
generation nitrogen-containing bisphosphonates such as
pamidronate, alendronate, risedronate and zoledronate
[10, 14, 17–24], but in the literature there are no reports of
ONJ in patients taking neridronate.
In this survey, we have not demonstrated any evidence
of ONJ as a side-effect of intravenous neridronate use in
children and adolescents treated for OI for a mean of
6.81 years and with a mean cumulative dose of 50 mg/kg.
We have not seen ONJ in patients treated with neridr-
onate who are still growing and who are often teething, a
potential risk factor for osteonecrosis due to the rapid
remodeling of jaw bone.
The most commonly reported initiating factor of ONJ is
tooth extraction, although periodontal disease and denture
trauma have been implicated [10, 11].
In the survey conducted by the Myeloma Foundation,
the mean time of osteonecrosis onset was 6 years in
patients receiving pamidronate and 18 months in patients
receiving zoledronic acid. Other reports suggest shorter
mean onset times, but few studies report onset when the
patient has been on treatment for \1 year. Long-term
studies of intravenous bisphosphonates have generally
covered approximately 2 years, which may have been too
short a time to identify this event [26].
In our study, we did not find cases of ONJ even in
patients who had been treated for nearly 13 years. ONJ is
probably not frequently found in OI patients because, in
spite of lengthy duration of therapy, low neridronate doses
are used. It is possible, however, that high cumulative
doses are needed to observe ONJ; cancer patients are
treated for bone metastasis with higher doses even if for a
shorter time.
The lack of comorbidities and the lower doses used in
children and adolescents probably reduce the risk of
osteonecrosis.
Most reported cases of ONJ are in adult cancer patients,
who are at a significantly higher risk of ONJ for several
reasons [10–13].
In adults, even though the incidence of ONJ is not
known, there seems to be a difference in prevalence
depending on the mode and frequency of administration,
drug potency, cumulative dose and the duration of
treatment.
The agents described in the literature as involved in ONJ
belong exclusively to the class of potent nitrogen-con-
taining bisphosphonates (zolendronic acid, alendronate,
risedronate and pamidronate) and it is evident that the
incidence of ONJ associated with parenteral bisphospho-
nates is higher than that with oral bisphosphonates [27].
Among the clinically-relevant bisphosphonates there are
significant differences in mineral binding affinities that
influence their differential distributions within bone, their
biological potencies and their duration of action. Neridro-
nate is a bisphosphonate that is structurally similar to
alendronate and pamidronate, but its retention time within
bone and the expression of its mineral binding affinity has
been reported as being lower than the retention time of
alendronate and pamidronate [28, 29].
Studies on adults taking neridronate will be important to
establish if the lower relative bone mineral-binding affinity
of neridronate might restrict osteoclastic function less
severely than other bisphosphonates, contributing to reduce
the risk of ONJ.
In children, only osteonecrosis of long bones has been
reported in patients treated for ALL [15, 16]. Corticoste-
roids are integral to the management of childhood ALL and
are probably what contributes to the dramatic increase in
the occurrence of osteonecrosis in children.
No case of ONJ has ever been reported in children;
therefore, the true incidence of this complication remains
unknown.
Table 1 Neridronate intravenous treatment in our patients
Type of OI Patients (n) Mean age at
the start of
treatment (years)
Mean length
of treatment
(years)
I 75 5.6 ± 3.6 6.7 ± 3.0
III 20 4.3 ± 4.3 6.9 ± 2.7
IV 4 9.6 ± 3.8 6.6 ± 5.5
Other types 3 2.0 ± 1.1 7.7 ± 2.7
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We advise the use of less potent bisphosphonates such
as neridronate in pediatric patients affected by OI.
It is recommended that prior to the initiation of bis-
phosphonate therapy, an evaluation of the dental status
should be performed to identify existing infections, com-
promised teeth and ill-fitting dentures. If bisphosphonate
therapy can be delayed, preventive surgery to eliminate
potential sites of infection should be performed.
The patients should be referred to a dentist for routine
examination, education and instruction.
Optimal dental health during treatment is essential and
all patients should be informed of the importance of good
oral hygiene [27, 30].
The requirement for dental treatment is higher in chil-
dren suffering from OI due to the frequent association with
dentinogenesis imperfecta.
In conclusion, at the moment there are insufficient data
available to prove a link between the use of neridronate and
ONJ in children. Young patients affected by OI do not seem
to be at a greater risk of ONJ than children and adolescents
affected by other forms of bone fragility. However, clini-
cians have to report every occurrence of ONJ in children
and adolescents treated with bisphosphonates because cases
may emerge in future. Prospective studies are also needed to
determine the safety of neridronate in adults.
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